Sustained Release Pellets Prepared by Extrusion-Spheronization: Advantages, Formulation Considerations, and Process Optimization

The design and development of oral drug delivery systems have undergone a paradigm shift over the past three decades. Traditional immediate-release (IR) dosage forms, while effective, often produce fluctuating plasma drug concentrations characterized by peak- trough oscillations that may result in toxic side effects at peak levels and subtherapeutic effects at trough levels. This pharmacokinetic limitation prompted the development of modified-release (MR) formulations, of which sustained release (SR) systems are the most widely investigated and clinically employed.

Sustained release drug delivery systems are designed to release the active pharmaceutical ingredient (API) at a predetermined, controlled rate over an extended period typically 8 to 24 hours thus maintaining plasma drug concentrations within the therapeutic window for a prolonged duration. This not only enhances therapeutic efficacy but also improves patient compliance, reduces dosing frequency, and minimizes adverse effects.

Within the domain of sustained release systems, multiparticulate dosage forms and pellets in particular have garnered substantial interest. Pellets are small, spherical or semi-spherical agglomerates of drug and excipients, typically ranging from 0.5 to 2.0 mm in diameter. Their multiparticulate nature imparts distinct pharmacokinetic and biopharmaceutical advantages, which will be discussed in detail in subsequent sections.

Extrusion-spheronization (ES), first described by Conine and Hadley in 1970, has since evolved into the most widely employed technique for pellet manufacture in pharmaceutical production. The process combines wet granulation, extrusion through a die, and spheronization on a friction plate to produce pellets of remarkable sphericity and narrow particle size distribution. When combined with appropriate matrix-forming or coating strategies, the ES technique produces sustained release pellets with excellent performance characteristics.

The objective of this review is to consolidate the current knowledge on sustained release pellets prepared by extrusion-spheronization, with a focus on the superiority of this dosage form and manufacturing technique, targeting readers in the pharmaceutical sciences community including undergraduate and postgraduate students, researchers, and clinicians.

2. SUSTAINED RELEASE DRUG DELIVERY SYSTEMS

2.1 Definition and Rationale

Sustained release (SR) systems, also referred to as extended release (ER), prolonged release, or controlled release systems, are formulations engineered to liberate the drug at a rate slower than that of conventional dosage forms. The USP defines extended- release dosage forms as those "that allow at least a twofold reduction in dosing frequency" compared to immediate-release formulations.

The primary rationale for developing SR systems lies in overcoming the pharmacokinetic shortcomings of IR formulations. For drugs with short half-lives, frequent dosing leads to patient non-compliance; for drugs with narrow therapeutic indices, the fluctuating plasma levels of IR dosage forms increase the risk of toxicity or therapeutic failure. SR systems address both challenges simultaneously.

2.2 Types of Modified Release Systems

Table .1Types of modified release system

2.3 Pharmacokinetic Advantages of SR Systems

The pharmacokinetic benefits of sustained release systems are well established in the literature. Figure-equivalent descriptions are provided below:

• Maintenance of plasma drug concentrations within the therapeutic window (Cmax reduced, Cmin elevated)
• Reduction of peak-trough fluctuation index (PTF%), leading to smoother concentration-time profiles
• Extended mean residence time (MRT) and area under the curve (AUC) per dose
• Reduced total daily dose requirement in many cases
• Decreased incidence of dose-related adverse effects
• Improved bioavailability for drugs susceptible to first-pass metabolism at high local concentrations

2.4 Mechanisms of Sustained Drug Release

Several physicochemical mechanisms govern drug release from SR systems. Understanding these mechanisms is fundamental to rational formulation design:

2.4.1 Matrix Diffusion

In hydrophilic or hydrophobic matrix systems, the drug is homogeneously dispersed within a polymer matrix. Drug release occurs by diffusion through water-filled pores (for hydrophilic matrices, e.g., HPMC) or through the polymer itself (for hydrophobic matrices, e.g., ethylcellulose, Eudragit RS). The release typically follows the Higuchi equation: Q = A√(D·Cs·(2Co - Cs)·t), where Q is the amount released, D is diffusivity, Cs is drug solubility, and Co is initial concentration.

2.4.2 Reservoir (Membrane) Diffusion

A drug core is surrounded by a rate-controlling polymer membrane. Drug diffuses through the membrane at a rate governed by the membrane thickness, permeability, and concentration gradient. This mechanism applies to coated pellets. Zero-order release kinetics can be achieved with reservoir systems when the membrane integrity is maintained.

2.4.3 Osmotic Pumping

Osmotic pressure drives fluid into the core through a semipermeable membrane, creating internal pressure that expels drug solution through a laser-drilled orifice. While not applicable to standard pellets, this mechanism is used in OROS tablets and some capsule- based systems.

2.4.4 Ion Exchange

Drug ions are bound to ion-exchange resins and released in the GI tract upon exchange with physiological ions. This mechanism provides pH-independent release and is used in some liquid SR formulations.

3. PELLETS AS A MULTIPARTICULATE DRUG DELIVERY SYSTEM

3.1 Definition and Characteristics

Pellets are spherical or nearly spherical granules ranging from 0.5 to 2.0 mm in diameter, prepared by the agglomeration of fine drug and excipient particles. According to the European Pharmacopoeia (Ph. Eur.), pellets are "spherical granules, typically between 0.5 and 2 mm in diameter." Ideal pellets possess:

• High sphericity (aspect ratio close to 1.0)
• Narrow particle size distribution (span < 1.0)
• Smooth surface with low friability
• High bulk density and good flowability
• Uniform drug distribution throughout the particle

3.2 Why Pellets are Superior to Conventional Tablets

The multiparticulate nature of pellets confers several pharmacokinetic, biopharmaceutical, and technological advantages over monolithic dosage forms such as tablets and capsules:

Table. 2 Comparision between SR Pellets to Conventional tablets

3.3 Methods of Pellet Preparation

Multiple techniques have been developed for pellet manufacture. Each technique has distinct advantages and limitations:

Table. 3 Methods of pellets preparation

4. EXTRUSION-SPHERONIZATION TECHNIQUE

4.1 Historical Background

The extrusion-spheronization process was first introduced by Conine and Hadley in 1970 as a method to produce spherical pellets using a friction plate spheronizer. The technique was further refined by Erkoboni (1997) and subsequently adopted across the pharmaceutical industry due to its ability to produce pellets with exceptional physical properties. The development of microcrystalline cellulose (MCC) as an extrusion aid by Avicel in the 1960s was pivotal to the widespread adoption of ES in pharmaceutical pelletization.

4.2 Process Description

Extrusion-spheronization is a multi-step process comprising the following sequential unit operations:

Step 1: Dry Mixing

The API and all excipients (MCC, fillers, binders) are blended in a suitable mixer (planetary mixer, high-shear granulator) until a homogeneous powder blend is achieved. This step ensures uniform drug distribution in the final pellets.

Step 2: Wet Granulation / Wet Massing

A granulating liquid (typically water, but also hydroalcoholic solutions containing binders such as hydroxypropyl methylcellulose or polyvinylpyrrolidone) is added to the powder blend and mixed to form a plastic, cohesive wet mass of the correct consistency. The water content is critical: too little results in crumbly extrudates, while too much yields elongated, sticky spaghetti-like extrudates that cannot spheronize properly.

Step 3: Extrusion

The wet mass is forced through a die plate containing circular orifices of defined diameter (typically 0.5–2.0 mm) using a radial, axial, or basket extruder. The extrudate exits as cylindrical rods of uniform diameter. The extrusion speed, die diameter, and die length-to- diameter ratio are critical process parameters governing extrudate quality and pellet yield.

Step 4: Spheronization

The freshly extruded cylindrical rods are transferred to the spheronizer, which consists of a static cylinder and a rotating friction plate (cross-hatch or radial groove pattern) at the bottom. The friction between the extrudate and the plate, combined with centrifugal and gravitational forces, causes the cylinders to break, round off, and form spherical pellets. Spheronization time (typically 2–10 minutes) and speed (500–2000 rpm) are critical parameters.

Step 5: Drying

The wet pellets are dried in a fluid bed dryer, tray oven, or other suitable drying equipment to achieve the desired moisture content (typically < 3% for most formulations). Drying conditions must be optimized to prevent pellet aggregation, cracking, or drug migration.

Step 6: Sizing / Screening

Dried pellets are sieved through appropriate mesh screens to collect the desired size fraction (e.g., 600–1000 μm). Oversized and undersized fractions may be recycled or re-processed.

Step 7: Coating (for SR Pellets)

For sustained release pellets, the sized pellets are coated with a rate-controlling polymer film in a fluid bed coater (Wurster process) or pan coater. Commonly used polymers include ethylcellulose (Surelease, Aquacoat ECD), Eudragit RS/RL, and cellulose acetate. The coating level (% weight gain), plasticizer type and concentration, and curing conditions determine the drug release profile.

4.3 Equipment Used in Extrusion-Spheronization

Table. 4 Equipment’s used in extrusion spheronization technique

4.4 Critical Formulation Variables

4.4.1 Microcrystalline Cellulose (MCC)

MCC is the quintessential extrusion aid in ES pelletization. Its unique properties — high water absorption capacity, plastic deformation under compression, and ability to form a coherent wet mass — make it indispensable in the ES process. MCC (Avicel PH-101, PH-102) is typically used at 30–70% w/w of the formulation. The water-holding capacity of MCC creates a viscoplastic mass that flows through the die without elastic springback and spheronizes efficiently. Other cellulosic extrusion aids include kappa-carrageenan and chitin.

4.4.2 Drug-MCC Ratio and Drug Loading

High drug loading (>60%) can compromise pellet sphericity and friability. The drug-to-MCC ratio must be carefully optimized. Drugs with low water solubility tend to disrupt the MCC network, while highly water-soluble drugs can over-plasticize the mass. Drug loads up to 80% have been achieved with careful formulation and process optimization.

4.4.3 Granulating Liquid

Water is the most common granulating liquid. The volume of granulating liquid and its addition rate critically influence wet mass consistency and pellet quality. Binders such as HPMC (1–5% w/v), PVP K30 (1–5% w/v), or sodium CMC may be dissolved in the granulating liquid to improve pellet hardness and drug loading capacity.

4.4.4 Sustained Release Polymers and Coating Formulation

The selection of the rate-controlling polymer is the most critical formulation decision for SR pellets. Key parameters include:

• Ethylcellulose (EC): Water-insoluble film former; used as aqueous dispersion (Surelease, Aquacoat ECD) or organic solution; excellent for pH-independent SR
• Eudragit RS/RL: Ammonio methacrylate copolymers; RS (permeable) blended with RL (more permeable) to modulate release; pH-independent
• Cellulose acetate: Used for osmotic systems; semi-permeable
• Shellac: Natural resin; pH-dependent dissolution (above pH 7.0)
• HPMC (Hypromellose): Hydrophilic matrix; swells and erodes to control release

Table .5 Polymers used to prepare sustain release pellets

5.1 Over Conventional Immediate-Release Dosage Forms

The advantages of SR pellets over conventional IR tablets and capsules are multifaceted, encompassing pharmacokinetic, pharmacodynamic, safety, patient compliance, and technological dimensions:

• Reduced dosing frequency: Drugs with short half-lives (e.g., propranolol t½ = 3–6 hr) require multiple daily doses as IR formulations; SR pellets allow once or twice daily dosing
• Smooth plasma concentration profile: SR pellets maintain drug concentration within the therapeutic window, minimizing toxic peaks and subtherapeutic troughs
• Improved patient adherence: Reduced dosing burden directly correlates with improved compliance in chronic disease management (hypertension, diabetes, epilepsy, Parkinson's disease)
• Reduced adverse effects: Lower Cmax reduces concentration-dependent adverse effects (e.g., GI irritation from NSAIDs, CNS side effects from opioids)
• Sustained therapeutic effect during sleep: Critical for drugs managing nocturnal or early-morning symptoms (e.g., antihypertensives, bronchodilators)

5.2 Over Monolithic SR Tablets

• Minimal dose-dumping risk: If a single SR tablet fails (mechanical fracture, improper manufacturing), the entire dose is released immediately — a risk virtually absent in multiparticulate pellets
• Flexible food interactions: Pellets < 2 mm in diameter pass through the pyloric sphincter independently of meal intake, unlike large tablets that are retained in the stomach during fed state
• Combination products: Pellets with different release profiles can be blended in a single capsule — e.g., IR pellets (20% dose) + SR pellets (80% dose) for rapid onset followed by sustained effect
• Sprinkle formulations: Pellets can be opened from capsules and sprinkled on food or dispersed in liquid for patients who cannot swallow (pediatrics, geriatrics, dysphagia patients)
• Lower local GI concentration: Drug is distributed over large intestinal surface area, reducing mucosal irritation

5.3 Advantages of Extrusion-Spheronization Over Other Pelletization Techniques

Among pelletization techniques, extrusion-spheronization offers a unique combination of advantages:

• Superior sphericity: ES produces pellets with aspect ratios approaching 1.0, ensuring uniform coating thickness and reproducible drug release profiles unmatched by fluidized bed agglomeration or hot-melt extrusion

• Narrow particle size distribution: Span values < 0.8 are routinely achieved, ensuring dose uniformity and predictable release kinetics
• High drug loading: ES can accommodate drug loads of 40–80% without compromising pellet quality, superior to drug layering on non-pareil beads
• Scalability: ES equipment scales linearly from laboratory (1 kg) to commercial (500 kg) scale with minimal re-optimization, supporting efficient technology transfer
• Cost-effective: Continuous process with high yield; equipment investment lower than more complex technologies (OROS, hot-melt extrusion)
• Solvent flexibility: Aqueous or hydroalcoholic granulating liquids can be used; no organic solvents required in standard ES
• Versatility: Compatible with hydrophilic and hydrophobic matrix systems, immediate and sustained release, enteric and gastroretentive formulations
• Excellent coating efficiency: Spherical pellets provide the most uniform, defect-free coating surface — critical for predictable SR performance

6. EVALUATION PARAMETERS FOR SR PELLETS

6.1 Physical Characterization

Table. 6 Physical characterization of SR Pellets

6.2 In Vitro Drug Release Testing

In vitro dissolution testing is the most critical quality attribute for SR pellets. The USP apparatus 2 (paddle) at 50–100 rpm or apparatus 1 (basket) in pH-change media (0.1 N HCl for 2 hr, then pH 6.8 phosphate buffer) is most commonly used. Acceptance criteria for SR pellets typically specify:

• Not less than (NLT) 20–30% release at 1–2 hours (burst release)
• 40–60% release at 4–6 hours (mid-point)
• NLT 80% release at 12–18 hours (complete release)

Release data are fitted to mathematical models to characterize the release mechanism:

Table .7 Kinetic study parameters fot SR Pellets

6.3 Similarity Factor (f2) Analysis

The f2 similarity factor, as defined by the FDA, is used to compare dissolution profiles between test and reference batches. An f2 value between 50 and 100 indicates similarity between two profiles and is a regulatory requirement for post-approval changes and scale-up. The formula is: f2 = 50 × log{[1 + (1/n)Σ(Rt - Tt)²]^-0.5 × 100}, where Rt and Tt are the mean percentage dissolved at each time point for reference and test, respectively.

7. SELECTED DRUG PRODUCTS AND CASE STUDIES

7.1 Marketed SR Pellet Products

Table. 8 Marketed products